GenSight Biologics S.A
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV… Read more
Market Cap & Net Worth: GenSight Biologics S.A (GSGTF)
GenSight Biologics S.A (PINK:GSGTF) has a market capitalization of $52.91 Million ($52.91 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #25316 globally and #8652 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GenSight Biologics S.A's stock price $0.24 by its total outstanding shares 220463002 (220.46 Million).
GenSight Biologics S.A Market Cap History: 2018 to 2025
GenSight Biologics S.A's market capitalization history from 2018 to 2025. Data shows change from $420.73 Million to $52.91 Million (-37.55% CAGR).
GenSight Biologics S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GenSight Biologics S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
47.03x
GenSight Biologics S.A's market cap is 47.03 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $420.73 Million | $4.35 Million | -$33.45 Million | 96.81x | N/A |
| 2019 | $649.77 Million | $700.00K | -$30.71 Million | 928.24x | N/A |
| 2020 | $1.89 Billion | $4.39 Million | -$34.02 Million | 430.99x | N/A |
| 2021 | $1.49 Billion | $5.28 Million | -$28.62 Million | 282.06x | N/A |
| 2022 | $694.46 Million | $2.58 Million | -$27.62 Million | 268.96x | N/A |
| 2023 | $103.62 Million | $1.27 Million | -$26.22 Million | 81.78x | N/A |
| 2024 | $70.55 Million | $1.50 Million | -$14.00 Million | 47.03x | N/A |
Competitor Companies of GSGTF by Market Capitalization
Companies near GenSight Biologics S.A in the global market cap rankings as of March 18, 2026.
Key companies related to GenSight Biologics S.A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
GenSight Biologics S.A Historical Marketcap From 2018 to 2025
Between 2018 and today, GenSight Biologics S.A's market cap moved from $420.73 Million to $ 52.91 Million, with a yearly change of -37.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $52.91 Million | -25.00% |
| 2024 | $70.55 Million | -31.91% |
| 2023 | $103.62 Million | -85.08% |
| 2022 | $694.46 Million | -53.33% |
| 2021 | $1.49 Billion | -21.42% |
| 2020 | $1.89 Billion | +191.45% |
| 2019 | $649.77 Million | +54.44% |
| 2018 | $420.73 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of GenSight Biologics S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $52.91 Million USD |
| MoneyControl | $52.91 Million USD |
| MarketWatch | $52.91 Million USD |
| marketcap.company | $52.91 Million USD |
| Reuters | $52.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.